Jubilant Pharmova Ltd. engages in the provision of basic organic chemicals. It operates through the following segments: Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, Contract Research Development and Manufacturing Organisation, Generics, and Proprietary Novel Drugs. The Radiopharma segment is involved in products for diagnosis and treatment of various diseases, including Pulmonary Embolism, Cancer, Coronary Artery Diseaseand many others. The Allergy Immunotherapy segment provides diagnostic devices for skin testing. The CDMO Sterile Injectables segment offer manufacturing services including sterile fill and finish injectables, full-service ophthalmic offer, and ampoules. The Generics segment includes development, manufacturing, distribution, sales and marketing of generics formulations. The CRDMO segment relates to drug discovery and development services. The company was founded on June 21, 1978 and is headquartered in Noida, India.
JUBILANT PHARMOVA LTD financial statements, including revenue, expenses, and profit: The total revenue of JUBLPHARMA for the last quarter is 19.01 B INR, and it's 1.46% lower compared to the previous quarter. The net income of Q1 25 is 1.03 B INR.
JUBILANT PHARMOVA LTD key financial stats and ratios: JUBLPHARMA price-to-sales ratio is 2.37. The company has an Enterprise Value to EBITDA ratio of 14.48. As of 2024 they employed 6.09 k people.
JUBILANT PHARMOVA LTD dividends overview: JUBLPHARMA dividends are paid annually. The last dividend per share was 5.00 INR. As of today, Dividend Yield (TTM)% is 0.45%.
JUBILANT PHARMOVA LTD earnings per share and revenue: JUBLPHARMA earnings per share for the last quarter are 6.50 INR whereas the estimation was 6.40 INR which accounts for 1.56% surprise. Company revenue for the same period amounts to 19.01 B INR despite the estimated figure of 18.87 B INR. Estimated earnings per share for the next quarter are 6.60 INR, and revenue is expected to reach 19.27 B INR. Also watch annual changes over time to get a bigger picture of JUBLPHARMA earnings per share and revenue dynamics.
JUBILANT PHARMOVA LTD revenue breakdown overview: JUBILANT PHARMOVA LTD revenue for the last year amounted to 72.34 B INR, the most of which — 33.88 B INR — came from its highest performing source at the moment, Radiopharma, the year earlier bringing 30.01 B INR. The greatest contribution to the revenue figure was made by Americas and Europe — last year it brought JUBILANT PHARMOVA LTD 65.94 B INR, and the year before that — 60.12 B INR.
Potential 50% Upside with Entry Price 1050 Target Price 1575, Timeframe 6-12 Months
Comments
Post a Comment